drugset

drugset / Trial / NCT00637819

Leflunomide in Systemic Lupus Erythematosus

NCT00637819 ↗

Phase 2 Completed 27 enrolled Sanofi

RandomizedSingle-groupOpen-labelTreatment

Summary

A pilot study to evaluate the efficacy and safety of leflunomide in SLE patients with active disease who are refractory to cyclophosphamide

Timeline

Start: 2003-01
Primary completion: —
Completion: 2004-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Leflunomide	Small molecule	20 mg	—

Indications